The U.S. Food and Drug Administration has approved Indianapolis-based Eli Lilly’s new treatment for moderate to severe eczema. It’s called Ebglyss.

Ebglyss is used as an injection to treat anyone 12 and older who also weighs at least 88 pounds.

“Patients still struggle to control their moderate-to-severe atopic dermatitis with currently available therapies. Many experience poor long-term disease control, and severe itch can significantly impact their daily lives,” said Jonathan Silverberg, M.D., Ph.D., M.P.H., professor of dermatology at George Washington University School of Medicine and Health Sciences in Washington, DC, and first author of the New England Journal of Medicine manuscript summarizing EBGLYSS clinical trials.2

Silverberg says the FDA approval of EBGLYSS is a “big win for patients, as we now have a new first-line biologic treatment option for moderate-to-severe disease when topical prescriptions aren’t enough.”

Lilly executives say two studies were done. They showed that 38% of people who took the injection achieved clear or “almost-clear” skin at 16 weeks, and 10% saw these results as early as four weeks. 43% of people who took ebglyss felt relief from itch at 16 weeks.

“Eczema can affect people of all skin tones, ethnicities, genders and ages. Nearly 16.5 million adults in the U.S. have eczema, with 6.6 million experiencing moderate-to-severe symptoms like itchiness, dry and scaly skin, discoloration and rashes, which can lead to more scratching that may cause skin to crack and bleed,”6 said Kristin Belleson, President and CEO of the National Eczema Association. “The approval of EBGLYSS provides hope and promise for the eczema community and those still seeking lasting relief from disruptive symptoms.”

Ebglyss will be available in the United States in the coming weeks.

Eczema is a chronic skin condition that causes dry, itchy and inflamed skin.